$1.78
8.23% today
Nasdaq, Sep 24, 05:16 pm CET
ISIN
US03835L1089
Symbol
APVO

Aptevo Therapeutics Inc Stock price

$1.64
-0.26 13.68% 1M
-44.76 96.47% 6M
-84.56 98.10% YTD
-128.38 98.74% 1Y
-101,585.56 100.00% 3Y
-236,058.36 100.00% 5Y
-3,646,718.36 100.00% 10Y
-3,646,718.36 100.00% 20Y
Nasdaq, Closing price Tue, Sep 23 2025
-0.05 2.96%
ISIN
US03835L1089
Symbol
APVO
Industry

Key metrics

Basic
Market capitalization
$5.4m
Enterprise Value
$-4.0m
Net debt
positive
Cash
$9.4m
Shares outstanding
3.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.2
P/B
0.8
Financial Health
Equity Ratio
30.5%
Return on Equity
-504.7%
ROCE
-226.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-24.0m | -
EBIT
$-24.3m | $-23.4m
Net Income
$-24.0m | $-1.0b
Free Cash Flow
$-24.5m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
5.8% | -
EBIT
6.3% | 6.5%
Net Income
3.7% | -4,235.4%
Free Cash Flow
0.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-32.5
FCF per Share
$-7.6
Short interest
3.1%
Employees
37
Rev per Employee
$0.0
Show more

Is Aptevo Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

Aptevo Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Aptevo Therapeutics Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Aptevo Therapeutics Inc forecast:

Buy
86%
Hold
14%

Financial data from Aptevo Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 10 10
6% 6%
-
- Research and Development Expense 14 14
6% 6%
-
-24 -24
6% 6%
-
- Depreciation and Amortization 0.26 0.26
41% 41%
-
EBIT (Operating Income) EBIT -24 -24
6% 6%
-
Net Profit -24 -24
4% 4%
-

In millions USD.

Don't miss a Thing! We will send you all news about Aptevo Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aptevo Therapeutics Inc Stock News

Positive
Proactive Investors
8 days ago
Aptevo Therapeutics (NASDAQ:APVO) saw its shares jump sharply after the company reported encouraging clinical data from its Phase 1b/2 RAINIER trial evaluating mipletamig, a first-in-class CD123 x CD3 bispecific antibody, in patients with newly diagnosed acute myeloid leukemia (AML) who are unfit for intensive chemotherapy. Aptevo said that Cohort 3 of the trial achieved a 100% remission rate, ...
Neutral
Accesswire
8 days ago
No dose-limiting toxicities or cytokine release syndrome observed in RAINIER to date; mipletamig shows consistently favorable safety and tolerability Trial progressing efficiently, Cohort 4 open for enrollment SEATTLE, WA / ACCESS Newswire / September 16, 2025 / Aptevo Therapeutics ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company developing novel bispecific and ...
Neutral
Accesswire
20 days ago
New candidates, APVO452 and APVO451, harness proprietary ADAPTIR-FLEXTM design to target prostate and multiple solid tumor cancers by simultaneously engaging tumor antigens, T cells, and immunosuppressive cells Mipletamig-driven clinical validation of the CRIS-7-derived CD3 binding domain underpins Aptevo's introduction of new, trispecific CD3-directed anti-cancer molecules SEATTLE, WASHINGTON ...
More Aptevo Therapeutics Inc News

Company Profile

Aptevo Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics to improve patients lives. Its pipeline includes APVO210, APVO436, ROR1 Candidate, and ALG.APV-527. The company was founded on February 22, 2016 and is headquartered in Seattle, WA.

Head office United States
CEO Marvin White
Employees 37
Founded 2016
Website aptevotherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today